RANI(RANI)
RANI
ANALYST COVERAGE7 analysts
BUY
▲ +834.6%upside to target
L $9.00
Med $10.00consensus
H $28.00Key MetricsTTM
Market Cap$69.89M
Revenue TTM—
Net Income TTM—
Free Cash Flow—
Gross Margin94.9%
Operating Margin-1093.0%
Net Margin-929.1%
Return on Equity-245.5%
Return on Assets-56.8%
Debt / Equity—
Current Ratio3.40
EPS TTM—
PRICE
Prev Close
1.09
Open
1.06
Day Range1.05 – 1.11
1.05
1.11
52W Range0.39 – 3.87
0.39
3.87
20% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-4.0x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.18
Market-like
TECHNICAL
RSI (14)
57
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 119 days
Sep 18
RANI News
About
Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Talat Imran
Website
Mir HashimChief Scientific Officer
Bella VazquezSenior Vice President of People & Administrative Services
Alireza JavadiChief Technical Officer
Jesper HoeilandHead of Strategy
Mir A. ImranExecutive Chairman
Svai S. SanfordChief Financial Officer
Talat ImranChief Executive Officer & Director
Arvinder DhallaVice President of Clinical Development
Kate McKinleyChief Business Officer